These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35625289)

  • 1. Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?
    Baracaldo-Santamaría D; Cala-Garcia JD; Medina-Rincón GJ; Rojas-Rodriguez LC; Calderon-Ospina CA
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.
    Hahn J; Choi JH; Chang MJ
    J Clin Pharm Ther; 2017 Dec; 42(6):661-671. PubMed ID: 28948652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.
    Stockmann C; Constance JE; Roberts JK; Olson J; Doby EH; Ampofo K; Stiers J; Spigarelli MG; Sherwin CM
    Clin Pharmacokinet; 2014 May; 53(5):429-54. PubMed ID: 24595533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients.
    Masich AM; Heavner MS; Gonzales JP; Claeys KC
    Curr Infect Dis Rep; 2018 Apr; 20(5):9. PubMed ID: 29619607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.
    Gómez-López A
    Clin Microbiol Infect; 2020 Nov; 26(11):1481-1487. PubMed ID: 32535150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to select an antifungal agent in critically ill patients.
    Dimopoulos G; Antonopoulou A; Armaganidis A; Vincent JL
    J Crit Care; 2013 Oct; 28(5):717-27. PubMed ID: 24018296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.
    Chen W; Zhang D; Lian W; Wang X; Du W; Zhang Z; Guo D; Zhang X; Zhan Q; Li P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
    Bellmann R; Smuszkiewicz P
    Infection; 2017 Dec; 45(6):737-779. PubMed ID: 28702763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.
    John J; Loo A; Mazur S; Walsh TJ
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.
    Keane S; Geoghegan P; Povoa P; Nseir S; Rodriguez A; Martin-Loeches I
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):839-847. PubMed ID: 30257597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study.
    Roberts JA; Sime F; Lipman J; Hernández-Mitre MP; Baptista JP; Brüggemann RJ; Darvall J; De Waele JJ; Dimopoulos G; Lefrant JY; Mat Nor MB; Rello J; Seoane L; Slavin MA; Valkonen M; Venditti M; Wong WT; Zeitlinger M; Roger C
    Crit Care Resusc; 2023 Mar; 25(1):1-5. PubMed ID: 37876989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.
    Novy E; Roger C; Roberts JA; Cotta MO
    Crit Care; 2023 Nov; 27(1):449. PubMed ID: 37981676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungals in Patients With Extracorporeal Membrane Oxygenation: Clinical Implications.
    Kriegl L; Hatzl S; Schilcher G; Zollner-Schwetz I; Boyer J; Geiger C; Hoenigl M; Krause R
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae270. PubMed ID: 38887481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungals: From Pharmacokinetics to Clinical Practice.
    Carmo A; Rocha M; Pereirinha P; Tomé R; Costa E
    Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
    Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
    Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of antifungal drugs with a focus on anidulafungin.
    Mazzei T; Novelli A
    Drugs; 2009; 69 Suppl 1():79-90. PubMed ID: 19877739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
    Tängdén T; Ramos Martín V; Felton TW; Nielsen EI; Marchand S; Brüggemann RJ; Bulitta JB; Bassetti M; Theuretzbacher U; Tsuji BT; Wareham DW; Friberg LE; De Waele JJ; Tam VH; Roberts JA;
    Intensive Care Med; 2017 Jul; 43(7):1021-1032. PubMed ID: 28409203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.